“Some Hope For Women with Marc Beer Renovia “

Renovia Inc., announced that it is set to move forward with its several new products after Marc Beer closed a $32 million Series B round and $10 million in Venture debt. Renovia Inc. is a startup based in Boston and co-founded by the former Aegerion Pharmaceuticals CEO.

The medtech company is looking to develop a number of diagnostic and therapeutic products for treatment of pelvic floor disorders including urinary incontinence in women. Researchers have estimated that over 250 million women across the world suffer from urinary incontinence. Renovia has made incredible progress with its Leva receiving FDA approval early last year.

The Longwood Fund joined the Series B round led by Missouri-based Ascension Ventures and New York-based Perceptive Advisors. Longwood Fund is a healthcare investment firm which invested early in Renovia Inc. The money has been used by Renovia to develop and test four more therapeutic and diagnostic products inclusive of a new generation of the Leva device.

Marc Beer said in a statement that he was thrilled to receive the support of a group of leading healthcare investors who have the same vision to better diagnose, treat and elevate the lives of women across the world who are affected by pelvic floor disorders. The company combines innovative and proprietary sensor technologies as well as form factors with a digitized platform to give its customers valuable date that informs new treatment options, drive greater understanding and knowledge of pelvic floor disorders. The efforts will eventually lead to reduced healthcare cost in the long-term.

Marc Beer has an extensive experience working in big healthcare companies and pharmaceuticals including OvaScience where he served as a strategic consultant. The company had expressed merger interests with Michigan-based Millendo Therapeutics.

About Marc Beer

With over 25 years of experience, Mr. Beer centered his career on development and commercialization in biotechnology, devices, pharmaceuticals and diagnostics. He founded Renovia along with Ramon Iglesias and Yolanda in 2016 and secured funding by successfully closing a Series A financing. Mr. Beer became the founding Chief Executive Officer of ViaCell, a biotechnology company which focused on the collection, development and preservation of umbilical cord blood stem cells. The company grew rapidly under his tenure to have over 300 employees and went public in 2015.

He served at jErytech Pharma as a member of board of directors. He held various capacities in Genzyme including vice President of Global Marketing. Prior to that, he served in various sales and marketing positions at Abbott Laboratories. He was a member of the Mass Life Science Board of the Commonwealth of Massachusetts as well as Biotechnology Industry Organization. Beer served as a founding chairman of Good Start Genetics’ compensation committee. He holds various capacities at Minerva Neurosciences Inc., Additionally, he is a member of Miami University Business Advisory Council and Notre Dame Research and Commercialization Advisory Committee aas well as Notre Dame Graduate Studies Research and Advisory Council. Marc Beer holds a BS degree from Miami University. Learn more: https://ideamensch.com/marc-beer/

Thanks to Matthew Autterson

Matthew Autterson has dedicated over 25 years to the industry of financial services. He currently serves as Board Member, President, and Chief Executive Officer of CNS Bioscience, INC., a clinical drug research company with a primary focus concerning neuropathic pain.

Autterson holds deep ties within the Colorado business climate, where his skills in wealth management, wealth management consulting, and private wealth management have earned him a great deal of success. As a graduate of the University of Denver Tax Program, Autterson began his career at First Trust Corporation, a subsidiary of Fiserv.

Autterson worked his way through the world of financial trust companies until he became president of Resources Trust Company, largely regarded as the biggest state-charted financial institutions in the USA. Autterson later sold Resources Trust Company in 1989 to SunAmerica which was acquired in 1998 for $18 billion.

As a long standing member of the Board of Directors of Falci Adaptive Biosystems, a non-profit focused on helping those suffering from neuromotor disabilities, Autterson’s interest in helping humanity has gained him much respect in the business world of his hometown, Denver, Colorado.

Mr. Autterson also holds a rich history pursuing his interest in giving back to the community– he has served on the Board of the Denver Zoo and Denver Zoological Foundation. Most touchingly, he has also served as Chairman of the Board of Directors of Denver Hospice. Several times throughout its history, Mr. Autterson’s donations have been the primary driving force behind the zoo’s success. His ties to the financial industry have brought in significant donations time and time again. Animal lovers have Matthew Autterson to thank for his uncanny ability to mix finances with the lighter side of life.

Matthew Autterson remains an integral part of the Colorado business world with his current endeavors as Board Member, President, and Chief Executive Officer (CEO) of CNS Bioscience, Inc., founded in 2013. If Autterson’s history is any telling of his track record, we are sure to see big, innovative, and exciting happenings take place in the name of neuropathic pain developments in coming years with Autterson at their head.